This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Renal disease				
Renal disease	Vasopressin 2 receptor (AVPR2; V2R)	<p>Studies in cell culture suggest that activating intracellular V2Rs could help treat nephrogenic diabetes insipidus (NDI). NDI occurs when the kidneys fail to respond to vasopressin and can be caused by mutations that result in misfolded V2Rs that fail to insert into the cell membrane. In canine kidney cells with a misfolded V2R, non-peptide V2R agonists rescued cell surface expression of the receptor and improved cellular function. Next steps include evaluating the agonists in patients.</p> <p>VA106483, an oral V2R agonist from Vantia Therapeutics Ltd., is in Phase II testing to treat incontinence.</p> <p>SciBX 2(28); doi:10.1038/scibx.2009.1118 Published online July 23, 2009</p>	Work is unpatented; licensing status not applicable	<p>Robben, J.H. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online July 6, 2009; doi:10.1073/pnas.0900130106 Contact: Peter M. T. Deen, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands e-mail: p.deen@ncmls.ru.nl</p>